Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the promotion of Jesse Thissen to the position of Chief Operating Officer (COO) with immediate effect.
Jesse has served as Head of Biometrics and has played an instrumental role in strengthening the Company’s operational capabilities, technical leadership and project delivery. During his tenure, he has led a number of strategic initiatives designed to improve operational efficiency, expand the Company’s service offering and enhance its ability to execute increasingly complex and larger-scale client engagements.
In his new role as Chief Operating Officer, Jesse will be responsible for overseeing the Company’s day-to-day operations, supporting continued excellence in project delivery while driving operational scalability and supporting the Company’s next phase of commercial growth.
Mike Whitlow, Executive Director of Physiomics, commented: “Jesse’s promotion to Chief Operating Officer reflects the exceptional leadership, innovation and ambition he has demonstrated throughout his time at Physiomics. He has been instrumental in delivering a number of important operational improvements which we believe will strengthen the Company for many years to come.
“These changes are enhancing the way we operate and position Physiomics to pursue larger and more strategically significant contracts, broaden our service offering and further improve the speed, quality and scalability of our delivery. As demand for our services continues to grow, Jesse’s leadership will be central to executing our strategy and creating long-term value for shareholders.
“On behalf of the Board, I congratulate Jesse on his appointment and look forward to working closely with him as we continue to build a stronger, more efficient and increasingly scalable business.”
Jesse Thissen, Chief Operating Officer, commented: “I am delighted to accept the role of Chief Operating Officer at such an important stage in Physiomics’ development. Over the past year, we have made strong progress in establishing Biometrics as a revenue-generating service line, while also laying the foundations for scalable, high-quality delivery across the business. Physiomics has a talented team with deep scientific and technical expertise, and I look forward to supporting the Company’s next phase of growth by strengthening operational execution, expanding our service offering and ensuring we continue to deliver excellent work to our clients.”
ENDS
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
